CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
Author:
Publisher
The American Association of Immunologists
Subject
Immunology,Immunology and Allergy
Reference41 articles.
1. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
3. Pembrolizumab versus Ipilimumab in Advanced Melanoma
4. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
5. PD-1 blockade induces responses by inhibiting adaptive immune resistance
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study;The Lancet Oncology;2024-07
2. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy;Antibodies;2024-04-18
3. Safety, Efficacy, and Biomarker Results of a Phase 1b/2 Study Combining the CD40 Agonist Mitazalimab with mFOLFIRINOX in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Results of the OPTIMIZE-1 Trial;2024
4. Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events;Immunological Reviews;2023-08-10
5. Fcγ-receptor-independent controlled activation of CD40 canonical signaling by novel therapeutic antibodies for cancer therapy;2023-07-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3